Yatiri Bio Inc. has joined NVIDIA Inception , a program that nurtures startups revolutionizing industries with technological advancements.
Yatiri Bio approaches oncology with a whole system perspective, incorporating patient data, organoids, proteomics, and machine learning to create models predictive of patient outcomes. Our models create a molecularly defined patient landscape with testable systems embedded within this landscape, revolutionizing drug discovery. Yatiri Bio models are used by the pharmaceutical industry to identify patients sensitive to their therapeutics, increase the likelihood of clinical approval, expand therapeutic markets, and identify novel therapeutic targets with well-defined patient selection criteria.
Joining NVIDIA Inception will help Yatiri Bio to optimize and scale our deep learning algorithms that drive our predictive models with access to training and GPU cloud credits. The program will also offer Yatiri Bio the opportunity to collaborate with industry-leading experts and other AI-driven organizations.
Dr. Pilgrim Jackson, CEO of Yatiri Bio stated that “The NVIDIA Inception Program is a game changer that allows us to significantly expand our AI/ML capabilities to develop accurate model systems across multiple indications. The end result is that our technology can bring efficacious therapies to the patients that need them. We are fortunate that such programs are available that can further enhance our product offering.”
NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.
#NVIDIAInception, #NVIDIA, #ai, #YatiriBio,